FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300972334> ?p ?o ?g. }

• W4300972334 abstract "Background Trimethylamine N‐oxide (TMAO) contributes to cardiovascular disease through its prothrombotic, proatherothrombotic, and proinflammatory effects. We aimed to evaluate whether residual risk of recurrent stroke of TMAO and its precursor choline remain among patients who received dual‐antiplatelet therapy and intensive lipid‐lowering therapy and with a low inflammation level (high‐sensitivity C‐reactive protein <2 mg/L on admission). Methods and Results Patients with ischemic stroke or transient ischemic attack were enrolled from the CNSR‐III (Third China National Stroke Registry) in China. Plasma TMAO and choline concentrations at baseline were measured in 9793 participants using liquid chromatography–mass spectrometry. The primary outcome was a new stroke within 1 year. Multivariable‐adjusted hazard ratios were calculated using Cox regression models to investigate the associations of TMAO and choline with stroke recurrence. Among all patients, elevated TMAO and choline levels were associated with an increased risk of recurrent stroke (adjusted hazard ratios, 1.28 [95% CI, 1.12–1.45]; and 1.50 [95% CI, 1.32–1.71], respectively). Moreover, elevated TMAO and choline levels were associated with an increased risk of recurrent stroke among patients who received dual‐antiplatelet therapy (1.65 [95% CI, 1.28–2.13]; and 1.70 [95% CI, 1.32–2.19], respectively), intensive lipid‐lowering therapy (1.49 [95% CI, 1.15–1.94]; and 1.49 [95% CI, 1.15–1.92], respectively), with high‐sensitivity C‐reactive protein <2 mg/L (1.39 [95% CI, 1.14–1.69]; and 1.88 [95% CI, 1.53–2.30], respectively), and concurrently received dual‐antiplatelet therapy, intensive lipid‐lowering therapy and with high‐sensitivity C‐reactive protein <2 mg/L (3.57 [95% CI, 1.73–7.38]; and 2.19 [95% CI, 1.16–4.16], respectively). Conclusions TMAO and choline were risk factors for recurrent stroke independent of dual‐antiplatelet therapy, intensive lipid‐lowering therapy at discharge, and low inflammation on admission." @default.
• W4300972334 created "2022-10-04" @default.
• W4300972334 creator A5012418853 @default.
• W4300972334 creator A5017100408 @default.
• W4300972334 creator A5019560977 @default.
• W4300972334 creator A5040442512 @default.
• W4300972334 creator A5047995132 @default.
• W4300972334 creator A5051608735 @default.
• W4300972334 creator A5058052126 @default.
• W4300972334 creator A5070273499 @default.
• W4300972334 creator A5074448585 @default.
• W4300972334 creator A5075764283 @default.
• W4300972334 creator A5084727198 @default.
• W4300972334 creator A5089894146 @default.
• W4300972334 date "2022-10-04" @default.
• W4300972334 modified "2023-10-03" @default.
• W4300972334 title "Residual Risk of Trimethylamine‐N‐Oxide and Choline for Stroke Recurrence in Patients With Intensive Secondary Therapy" @default.
• W4300972334 cites W1845211636 @default.
• W4300972334 cites W2044638285 @default.
• W4300972334 cites W2046971089 @default.
• W4300972334 cites W2058735127 @default.
• W4300972334 cites W2078599166 @default.
• W4300972334 cites W2115944543 @default.
• W4300972334 cites W2162078360 @default.
• W4300972334 cites W2207436601 @default.
• W4300972334 cites W2231380317 @default.
• W4300972334 cites W2288501492 @default.
• W4300972334 cites W2295882128 @default.
• W4300972334 cites W2583372114 @default.
• W4300972334 cites W2609064408 @default.
• W4300972334 cites W2767806634 @default.
• W4300972334 cites W2829671626 @default.
• W4300972334 cites W2856619263 @default.
• W4300972334 cites W2884566703 @default.
• W4300972334 cites W2903641122 @default.
• W4300972334 cites W2954381706 @default.
• W4300972334 cites W3007010359 @default.
• W4300972334 cites W3045783780 @default.
• W4300972334 cites W3081761942 @default.
• W4300972334 cites W3136169513 @default.
• W4300972334 cites W3173211215 @default.
• W4300972334 cites W3190204978 @default.
• W4300972334 cites W3209828359 @default.
• W4300972334 cites W3215553963 @default.
• W4300972334 cites W4225433529 @default.
• W4300972334 doi "https://doi.org/10.1161/jaha.122.027265" @default.
• W4300972334 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36193936" @default.
• W4300972334 hasPublicationYear "2022" @default.
• W4300972334 type Work @default.
• W4300972334 citedByCount "3" @default.
• W4300972334 countsByYear W43009723342023 @default.
• W4300972334 crossrefType "journal-article" @default.
• W4300972334 hasAuthorship W4300972334A5012418853 @default.
• W4300972334 hasAuthorship W4300972334A5017100408 @default.
• W4300972334 hasAuthorship W4300972334A5019560977 @default.
• W4300972334 hasAuthorship W4300972334A5040442512 @default.
• W4300972334 hasAuthorship W4300972334A5047995132 @default.
• W4300972334 hasAuthorship W4300972334A5051608735 @default.
• W4300972334 hasAuthorship W4300972334A5058052126 @default.
• W4300972334 hasAuthorship W4300972334A5070273499 @default.
• W4300972334 hasAuthorship W4300972334A5074448585 @default.
• W4300972334 hasAuthorship W4300972334A5075764283 @default.
• W4300972334 hasAuthorship W4300972334A5084727198 @default.
• W4300972334 hasAuthorship W4300972334A5089894146 @default.
• W4300972334 hasBestOaLocation W43009723341 @default.
• W4300972334 hasConcept C126322002 @default.
• W4300972334 hasConcept C127413603 @default.
• W4300972334 hasConcept C185592680 @default.
• W4300972334 hasConcept C207103383 @default.
• W4300972334 hasConcept C2776149385 @default.
• W4300972334 hasConcept C2780645631 @default.
• W4300972334 hasConcept C2780924926 @default.
• W4300972334 hasConcept C2781123555 @default.
• W4300972334 hasConcept C44249647 @default.
• W4300972334 hasConcept C50382708 @default.
• W4300972334 hasConcept C55493867 @default.
• W4300972334 hasConcept C71924100 @default.
• W4300972334 hasConcept C78519656 @default.
• W4300972334 hasConcept C90924648 @default.
• W4300972334 hasConceptScore W4300972334C126322002 @default.
• W4300972334 hasConceptScore W4300972334C127413603 @default.
• W4300972334 hasConceptScore W4300972334C185592680 @default.
• W4300972334 hasConceptScore W4300972334C207103383 @default.
• W4300972334 hasConceptScore W4300972334C2776149385 @default.
• W4300972334 hasConceptScore W4300972334C2780645631 @default.
• W4300972334 hasConceptScore W4300972334C2780924926 @default.
• W4300972334 hasConceptScore W4300972334C2781123555 @default.
• W4300972334 hasConceptScore W4300972334C44249647 @default.
• W4300972334 hasConceptScore W4300972334C50382708 @default.
• W4300972334 hasConceptScore W4300972334C55493867 @default.
• W4300972334 hasConceptScore W4300972334C71924100 @default.
• W4300972334 hasConceptScore W4300972334C78519656 @default.
• W4300972334 hasConceptScore W4300972334C90924648 @default.
• W4300972334 hasIssue "19" @default.
• W4300972334 hasLocation W43009723341 @default.
• W4300972334 hasLocation W43009723342 @default.
• W4300972334 hasLocation W43009723343 @default.
• W4300972334 hasOpenAccess W4300972334 @default.
• W4300972334 hasPrimaryLocation W43009723341 @default.
• W4300972334 hasRelatedWork W2737419352 @default.

• next